Bleeding clinical trials at University of California Health
1 research study open to eligible people
Amplatzer Amulet LAAO vs. NOAC
open to eligible people ages 18 years and up
The objective of this trial is to evaluate the safety and effectiveness of the Amulet LAA occluder compared to NOAC therapy in patients with non-valvular AF at increased risk for ischemic stroke and who are recommended for long-term NOAC therapy. The clinical investigation is a prospective, randomized, multicenter active control worldwide trial. Subjects will be randomized in a 1:1 ratio between the Amulet LAA occlusion device ("Device Group") and a commercially available NOAC medication ("Control Group"). The choice of NOAC in the Control Group will be left to study physician discretion.
at UCSD
Our lead scientists for Bleeding research studies include Ryan Reeves, MD.
Last updated: